NEW YORK (GenomeWeb News) – BioFocus DPI said this week that it has extended a drug screening pact with drug giant Eli Lilly until the end of 2009.
Under terms of the deal, BioFocus, which is the service division of Galapagos, will identify active compounds by screening Lilly's library of drug candidates. BioFocus has been conducting research work on compounds that target specific cellular signal transduction pathways for Lilly since March 2005.
Financial and other terms of the collaboration were not disclosed.